Full Press Release Details
Biote Reports Third Quarter 2023 Financial Results
Achieves Progress in Test of Complementary Wellness Therapeutics
Reiterates 2023 Financial Guidance
IRVING, TX November 7, 2023 Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of
personalized hormone therapy, today announced financial results for the third quarter ended September 30, 2023.
Third Quarter 2023 Financial
(All financial result comparisons made are against the prior year period)
During the third quarter, Biote generated continued growth in revenue
and Adjusted EBITDA, reflecting patient demand for our hormone optimization and wellness therapies, said Terry Weber, Biote s Chief Executive Officer. Adjusted EBITDA margin remained strong, again demonstrating the profitability of
our business even as we invested in building our capabilities and broadening our geographic reach.
Ms. Weber continued, During the
quarter, we continued to advance our strategic priorities. We are pleased with the progress we have achieved in our commercial trials of complementary wellness therapeutics, including products for sexual health, weight loss and preventive wellness.
Based on the positive initial response to our expanded wellness offerings, we believe a national roll-out of these products is likely to resonate strongly with both our patients and practitioners. In
men s health, we are addressing the unmet needs of this large and growing market by driving greater awareness within our existing practitioner network and by engaging with key opinion leaders in the field. As the preventative health market
evolves, we believe Biote remains well-positioned for continued profitable growth given our leading presence, unparalleled operating experience and evidence-backed protocols that promote patient health and well-being.
2023 Third Quarter Financial Review
(All financial result comparisons made are against the prior year period unless otherwise noted)
Revenue for the third quarter of 2023 was $45.6 million, an increase of 8.5% from $42.0 million for the third quarter of 2022. The increase in
revenue was driven by procedure revenue growth of 7.4% and dietary supplement revenue growth of 5.1%. As expected, third quarter dietary supplement revenue growth moderated from the rate in the second quarter of 2023, reflecting the absence of a
seasonal promotion for Biote practitioners.
Gross profit margin for the third quarter of 2023 was 68.9% compared to 68.2% for the third quarter of 2022.
The increase in gross profit margin reflected continued effective cost management.
Operating income for the third quarter of 2023 was $7.6 million,
compared to $7.8 million for the third quarter of 2022. Operating income in the third quarter of 2023 was essentially unchanged as growth in revenue and improved gross profit were offset by increased personnel and other expenses to build our
Net income for the third quarter of 2023 was $19.6 million, representing a margin of 43.1%, and $0.25 per basic share, compared to
net income of $0.5 million, representing a margin of 1.2%, and $0.00 per share, for the third quarter of 2022. Net income and net income margin for the third quarter of 2023 primarily reflected a $17.5 million gain due to a change in the
fair value of the earnout liability. Net income and net income margin for the third quarter of 2022 were impacted by the net change in the fair value adjustments to the warrant and earnout liabilities.
Adjusted EBITDA for the third quarter of 2023 was $14.0 million with an Adjusted EBITDA margin of 30.8%, compared to Adjusted EBITDA of
$12.2 million, with an Adjusted EBITDA margin of 29.2% for the third quarter of 2022. The increase in Adjusted EBITDA and Adjusted EBITDA margin was due to growth in revenue and improved gross profit.1
2023 Financial Outlook
Biote remains committed to driving profitable growth through the consistent execution of our strategy. We reiterate our guidance that 2023 revenue and
Adjusted EBITDA2 will likely be toward the lower end of our guidance range, concluded Ms. Weber.
| ($ in millions) | 2023 Guidance Range | |
| Revenue | $190-$200 | |
| Adjusted EBITDA | $56-$60 |
Biote management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, November 8,
2023. To access the conference call by telephone, please dial (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). To access a live webcast of the call,
interested parties may use the following link: Biote Q3 2023 Earnings Webcast. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, at ir.biote.com, shortly after the event concludes.
Discussion of Non-GAAP Financial Measures
To provide investors with additional information regarding our financial results, Biote has disclosed Adjusted EBITDA, a
non-GAAP financial measure that it calculates as net income before interest, taxes and depreciation and amortization, further adjusted to exclude stock-based compensation, litigation expenses, legal
settlements, transaction-related expenses, merger and acquisition expenses, fair value adjustments to certain equity instruments classified as liabilities and other expenses. Below we have provided a reconciliation of Adjusted EBITDA to net income,
the most directly comparable GAAP financial measure.
We present Adjusted EBITDA and Adjusted EBITDA margin because it is a key measure used by our
management to evaluate our operating performance, generate future operating plans and determine payments under compensation programs. Accordingly, we believe that Adjusted EBITDA and Adjusted EBITDA margin provide useful information to investors and
others in understanding and evaluating our operating results in the same manner as our management.
Adjusted EBITDA and Adjusted EBITDA margin have
limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are as follows:
In addition, Adjusted EBITDA and Adjusted EBITDA margin are subject to inherent limitations as it reflects the
exercise of judgment by Biote s management about which expenses are excluded or included. A reconciliation is provided in the financial statement tables included below in this press release for each
non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Because of these limitations, you should consider Adjusted EBITDA and Adjusted EBITDA margin
alongside other financial performance measures, including net income and our other GAAP results.
Forward-Looking Non-GAAP Financial Measures
The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable GAAP
financial measures because it could not do so without unreasonable effort due to the unavailability of certain information needed to calculate reconciling items. For example, the Company has not included a reconciliation of projected Adjusted EBITDA
to GAAP net income (loss), which is the most directly comparable GAAP measure, for the periods presented in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K.
The Company s projected Adjusted EBITDA excludes certain items that are inherently uncertain and difficult to predict including, but not limited to, share-based compensation expense, income taxes, due diligence expenses and legal expenses. Due
to the variability, complexity and limited visibility of the adjusting items that would be excluded from projected Adjusted EBITDA in future periods, management does not forecast them for internal use and therefore cannot create a quantitative
projected Adjusted EBITDA to GAAP net income (loss) reconciliation for the periods presented without unreasonable efforts. A quantitative reconciliation of projected Adjusted EBITDA to GAAP net income (loss) for the periods presented would imply a
degree of precision and certainty as to these future items that does not exist and could be confusing to investors. From a qualitative perspective, it is anticipated that the differences between projected Adjusted EBITDA to GAAP net income (loss)
for the periods presented will consist of items similar to those described in the financial tables later in this release, including, for example and without limitation, share-based compensation expense, income taxes, due diligence expenses and legal
expenses. The timing and amount of any of these excluded items could significantly impact the Company s GAAP net income (loss) for a particular period. When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis.
Biote is transforming healthy aging through innovative, personalized hormone optimization therapies delivered by Biote-certified medical providers. Biote
trains practitioners how to identify and treat early indicators of hormone-related aging conditions, an underserved $7 billion global market, providing affordable symptom relief for patients and driving clinic success for practitioners.
Forward-Looking Statements
Except for historical
information contained herein, this press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words may, can, should, will,
estimate, plan, project, forecast, intend, expect, hope, anticipate, believe, seek, target, continue,
could, might, ongoing, potential, predict, would and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions,
projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from
those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their
patients; our customers reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our
customers sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all;
our ability to grow our business; the significant competition we face in our industry; our limited operating history; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or
regulations; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including recent bank failures; and future exchange
and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the Risk Factors section of Biote s Quarterly Report on Form
10-Q for the quarter ended June 30, 2023, filed with the SEC on August 11, 2023. These filings identify and address other important risks and uncertainties that could cause actual events and results
to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements,
and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve
Consolidated Balance
| September 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 65,575 | $ | 79,231 | ||||
| Short-term investment | 20,000 | |||||||
| Accounts receivable, net | 10,177 | 6,948 | ||||||
| Inventory, net | 11,078 | 11,183 | ||||||
| Other current assets | 10,923 | 3,816 | ||||||
| Total current assets | 117,753 | 101,178 | ||||||
| Property and equipment, net | 1,353 | 1,504 | ||||||
| Capitalized software, net | 5,449 | 5,073 | ||||||
| Operating lease right-of-use assets | 1,953 | 2,052 | ||||||
| Deferred tax asset | 23,241 | 1,838 | ||||||
| Total assets | $ | 149,749 | $ | 111,645 | ||||
| Liabilities and Stockholders Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 5,694 | $ | 4,112 | ||||
| Accrued expenses | 10,279 | 6,274 | ||||||
| Term loan, current | 6,250 | 6,250 | ||||||
| Deferred revenue, current | 2,562 | 1,965 | ||||||
| Operating lease liabilities, current | 298 | 165 | ||||||
| Total current liabilities | 25,083 | 18,766 | ||||||
| Term loan, net of current portion | 107,990 | 112,086 | ||||||
| Deferred revenue, net of current portion | 1,182 | 926 | ||||||
| Operating lease liabilities, net of current portion | 1,761 | 1,927 | ||||||
| TRA liability | 18,528 | |||||||
| Warrant liability | 4,104 | |||||||
| Earnout liability | 46,470 | 32,110 | ||||||
| Total liabilities | 201,014 | 169,919 | ||||||
| Commitments and contingencies (See Note 18) | ||||||||
| Stockholders Deficit | ||||||||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2023 and December 31, 2022 | ||||||||
| Class A common stock, $0.0001 par value, 600,000,000 shares authorized; 33,940,353 and 11,242,887 shares issued, 35,527,853 and 9,655,387 shares outstanding as of September 30, 2023 and December 31, 2022, respectively | 3 | 1 | ||||||
| Class V voting stock, $0.0001 par value, 100,000,000 shares authorized; 38,819,066 and 58,565,824 shares issued, 28,819,066 and 48,565,824 shares outstanding as of September 30, 2023 and December 31, 2022, respectively | 3 | 5 | ||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | (40,522 | ) | (44,460 | ) | ||||
| Accumulated other comprehensive loss | (13 | ) | (5 | ) | ||||
| biote Corp. s stockholders deficit | (40,529 | ) | (44,459 | ) | ||||
| Noncontrolling interest | (10,736 | ) | (13,815 | ) | ||||
| Total stockholders deficit | (51,265 | ) | (58,274 | ) | ||||
| Total liabilities and stockholders deficit | $ | 149,749 | $ | 111,645 |
Consolidated Statements of Operations
(In Thousands, except per share values)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product revenue | $ | 44,831 | $ | 41,574 | $ | 137,638 | $ | 119,121 | ||||||||
| Service revenue | 726 | 396 | 2,019 | 1,351 | ||||||||||||
| Total revenue | 45,557 | 41,970 | 139,657 | 120,472 | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Cost of products | 13,070 | 12,750 | 41,089 | 37,391 | ||||||||||||
| Cost of services | 1,097 | 587 | 2,783 | 1,760 | ||||||||||||
| Cost of revenue | 14,167 | 13,337 | 43,872 | 39,151 | ||||||||||||
| Selling, general and administrative | 23,791 | 20,818 | 72,636 | 149,346 | ||||||||||||
| Income (loss) from operations | 7,599 | 7,815 | 23,149 | (68,025 | ) | |||||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest expense, net | (1,530 | ) | (1,408 | ) | (4,821 | ) | (2,478 | ) | ||||||||
| Gain (loss) from change in fair value of warrant liability | 1,153 | (13,411 | ) | 4,552 | ||||||||||||
| Gain (loss) from change in fair value of earnout liability | 17,450 | (6,840 | ) | (14,360 | ) | 54,840 | ||||||||||
| Loss from extinguishment of debt | (445 | ) | ||||||||||||||
| Other income (expense) | (3 | ) | 8 | (14 | ) | 23 | ||||||||||
| Total other income (expense), net | 15,917 | (7,087 | ) | (32,606 | ) | 56,492 | ||||||||||
| Income (loss) before provision for income taxes | 23,516 | 728 | (9,457 | ) | (11,533 | ) | ||||||||||
| Income tax expense (benefit) | 3,874 | 234 | 5,426 | (48 | ) | |||||||||||
| Net income (loss) | 19,642 | 494 | (14,883 | ) | (11,485 | ) | ||||||||||
| Less: Net income (loss) attributable to noncontrolling interest | 12,112 | 479 | (10,465 | ) | (8,894 | ) | ||||||||||
| Net income (loss) attributable to biote Corp. stockholders | 7,530 | 15 | (4,418 | ) | (2,591 | ) | ||||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation adjustments | 8 | (1 | ) | 8 | ||||||||||||
| Other comprehensive income (loss) | 8 | (1 | ) | 8 | ||||||||||||
| Comprehensive income (loss) | $ | 19,650 | $ | 493 | $ | (14,875 | ) | $ | (11,485 | ) | ||||||
| Net income (loss) per common share | ||||||||||||||||
| Basic | $ | 0.25 | $ | 0.00 | $ | (0.19 | ) | $ | (0.34 | ) | ||||||
| Diluted | $ | 0.24 | $ | 0.00 | $ | (0.19 | ) | $ | (0.34 | ) | ||||||
| Weighted average common shares outstanding | ||||||||||||||||
| Basic | 30,334,193 | 7,605,031 | 22,921,401 | 7,596,379 | ||||||||||||
| Diluted | 31,041,245 | 7,605,031 | 22,921,401 | 7,596,379 |
Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||||||||
| 2023 | 2022 | |||||||
| Operating Activities | ||||||||
| Net loss | $ | (14,883 | ) | $ | (11,485 | ) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization | 1,484 | 1,644 | ||||||
| Bad debt expense (recoveries) | 624 | (210 | ) | |||||
| Amortization of debt issuance costs | 591 | 392 | ||||||
| Provision for obsolete inventory | (32 | ) | 80 | |||||
| Non-cash lease expense | 423 | 175 | ||||||
| Shares issued in settlement of litigation | 1,199 | |||||||
| Non-cash sponsor share transfers | 7,216 | |||||||
| Non-cash fees under SEPA | 108 | |||||||
| Share-based compensation expense | 7,060 | 80,016 | ||||||
| (Gain) loss from change in fair value of warrant liability | 13,411 | (4,552 | ) | |||||
| (Gain) loss from change in fair value of earnout liability | 14,360 | (54,840 | ) | |||||
| Loss from extinguishment of debt | 445 | |||||||
| Deferred income taxes | 394 | (597 | ) | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (3,834 | ) | (2,194 | ) | ||||
| Inventory | 137 | (646 | ) | |||||
| Other current assets | (7,118 | ) | (3,999 | ) | ||||
| Accounts payable | 1,582 | 4,476 | ||||||
| Deferred revenue | 853 | 344 | ||||||
| Accrued expenses | 4,005 | (31,396 | ) | |||||
| Operating lease liabilities | (329 | ) | (185 | ) | ||||
| Net cash provided by (used in) operating activities | 19,927 | (15,208 | ) | |||||
| Investing Activities | ||||||||
| Purchases of short-term investments | (20,000 | ) | ||||||
| Purchases of property and equipment | (518 | ) | (328 | ) | ||||
| Purchases of capitalized software | (1,191 | ) | (1,199 | ) | ||||
| Net cash used in investing activities | (21,709 | ) | (1,527 | ) | ||||
| Financing Activities | ||||||||
| Proceeds from the business combination | 12,282 | |||||||
| Principal repayments on term loan | (4,687 | ) | (2,813 | ) | ||||
| Borrowings on term loan | 125,000 | |||||||
| Extinguishment of Bank of America term loan | (36,250 | ) | ||||||
| Debt issuance costs | (4,036 | ) | ||||||
| Settlement of phantom equity rights | (7,250 | ) | ||||||
| Proceeds from exercise of stock options | 420 | |||||||
| Distributions | (7,588 | ) | (10,610 | ) | ||||
| Capitalized transaction costs | (8,341 | ) | ||||||
| Proceeds from issuance of shares under SEPA | 156 | |||||||
| SEPA transaction costs | (702 | ) | ||||||
| Net cash provided by (used in) financing activities | (11,855 | ) | 67,436 | |||||
| Effect of exchange rate changes on cash and cash equivalents | (19 | ) | (6 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | (13,656 | ) | 50,695 | |||||
| Cash and cash equivalents at beginning of period | 79,231 | 26,766 | ||||||
| Cash and cash equivalents at end of period | $ | 65,575 | $ | 77,461 | ||||
| Supplemental Disclosure of Cash Flow Information | ||||||||
| Cash paid for interest | $ | 7,022 | $ | 2,488 | ||||
| Cash paid for income taxes | $ | 2,789 | $ | 111 | ||||
| Non-cash investing and financing activities | ||||||||
| Capital expenditures and capitalized software included in accounts payable | $ | $ | 122 | |||||
| Non-cash SEPA transaction costs | $ | $ | 108 |
Reconciliation of Adjusted EBITDA to Net (Loss) Income
The following table presents a reconciliation of net income to Adjusted EBITDA, as well as the calculation of net income (loss) margin and Adjusted EBITDA
margin, for each of the periods indicated.
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net income (loss) | $ | 19,642 | $ | 494 | $ | (14,883 | ) | $ | (11,485 | ) | ||||||
| Interest expense, net | 1,530 | 1,408 | 4,821 | 2,478 | ||||||||||||
| Income tax expense (benefit) | 3,874 | 234 | 5,426 | (48 | ) | |||||||||||
| Depreciation and amortization | 416 | 580 | 1,484 | 1,644 | ||||||||||||
| Loss from extinguishment of debt (1) | 445 | |||||||||||||||
| Share-based compensation expense (2) | 2,243 | 746 | 7,060 | 80,016 | ||||||||||||
| Litigation expenses-former owner (3) | 2,738 | 1,617 | 4,807 | 1,784 | ||||||||||||
| Litigation-other (4) | 112 | 3 | 480 | 477 | ||||||||||||
| Legal settlement (gain) loss (5) | 50 | 1,248 | (62 | ) | ||||||||||||
| Transaction-related expenses (6) | 290 | 1,172 | 2,086 | 20,649 | ||||||||||||
| Other expenses (7) | 40 | 297 | 649 | 503 | ||||||||||||
| Merger and acquisition expenses (8) | 552 | 733 | ||||||||||||||
| (Gain) loss from change in fair value of warrant liability | (1,153 | ) | 13,411 | (4,552 | ) | |||||||||||
| (Gain) loss from change in fair value of earnout liability | (17,450 | ) | 6,840 | 14,360 | (54,840 | ) | ||||||||||
| Adjusted EBITDA | $ | 14,037 | $ | 12,238 | $ | 41,682 | $ | 37,009 | ||||||||
| Total revenue | $ | 45,557 | $ | 41,970 | $ | 139,657 | $ | 120,472 | ||||||||
| Net income (loss) margin (9) | 43 | % | 1 | % | (11 | )% | (10 | )% | ||||||||
| Adjusted EBITDA margin (10) | 31 | % | 29 | % | 30 | % | 31 | % |